Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (MALS & SPR verified), Unconjugated

Product Overview

• Article Name: Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (MALS & SPR verified), Unconjugated
• Biozol Catalog Number: ABS-HL1-H52E7-200UG
• Supplier Catalog Number: HL1-H52E7-200ug
• Alternative Catalog Number: ABS-HL1-H52E7-200UG
• Manufacturer: AcroBiosystems
• Host: Human
• Category: Proteine/Peptide
• Species Reactivity: Human
• Conjugation: Unconjugated

Product Description

NYESO1, which is also wellknown as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancertestis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLAA2 restricted NYESO1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatmentrefractory melanoma patients. The Human HLAA*0201 NYESO1 (SLLMWITQV) complex protein is a complex of HLAA*0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NYESO1. - Proteine/Peptide

Product Properties

• Molecular Weight: 36.3 kDa, 13.8 kDa and 13.3 kDa
• Tag: C-10*His
• NCBI: 59606
• Buffer: PBS, pH7.4
• Purity: 90%
• Form: Powder
• Target: HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQV)

Images

Immobilized Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (Cat. No. HL1-H52E7) at 5 µg/mL (100 µL/well) can bind Anti-NY-ESO-1 Antibody, Human IgG1 with a linear range of 0.3-5 ng/mL (QC tested).

Immobilized Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (Cat. No. HL1-H52E7) at 1 µg/mL (100 µL/well) can bind Anti-B2M Antibody, Human IgG1 with a linear range of 0.1-1 ng/mL (Routinely tested).

Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

HL1-H52E7-200ug